Clara cell protein (CC16) in pleural fluids: a marker of leakage through the visceral pleura.
Pleural fluid (PF) proteins either derive from serum by diffusion or are locally secreted within the pleural space. Another hypothetical origin is a leakage of lung secretory proteins across the visceral pleura. To test this hypothesis, we investigated the occurrence, sources, and determinants in PF of CC16, a small-size and readily diffusible protein of 16 kDa secreted by bronchiolar Clara cells. CC16 concentration was determined by a sensitive latex immunoassay in serum and PF of 117 subjects (86 exudates and 31 transudates) and, for purpose of comparison, in ascites samples from another group of 38 subjects (7 exudates and 31 transudates). CC16 was also studied in serum and PF of normal rats and in rats with pleural exudate induced by alpha-naphthyl-thiourea (ANTU). The levels of CC16 in PF and ascites were highly correlated with that in serum, suggesting a diffusional exchange across the pleural/blood and peritoneal/blood barriers. Whereas CC16 occurs at similar levels in ascites and serum, the protein was found to be more concentrated in PF than in serum in both humans (geometric mean in microg/L, 26.2 versus 14.6, p < 0.0001) and rats (213 versus 16.2, p < 0.001). A local synthesis of CC16 appeared unlikely in view of the lack of CC16-immunostaining in pleura of both species. The only plausible explanation for these findings is that CC16 in PF originates from two sources: diffusion from plasma and a leakage from the lung into the pleural space across the semipermeable visceral pleura. This interpretation is supported by a markedly increased leakage of CC16 in experimental exudates induced by ANTU and the finding of high CC16 concentrations in human transudates associated with congestive heart failure, two conditions wherein PF has been shown to arise from the interstitial spaces of the lung.
Hermans
C
C
Department of Pathology, Cliniques Universitaires Saint-Luc, Catholic University of Louvain, Brussels, Belgium.
Lesur
O
O
Weynand
B
B
Pieters
T
T
Lambert
M
M
Bernard
A
A
D000368:Aged; D000818:Animals; D001201:Ascites / Q000378:metabolism; D015415:Biomarkers / Q000032:analysis; D001798:Blood Proteins / Q000032:analysis; D001980:Bronchi / Q000378:metabolism; D003404:Creatinine / Q000097:blood; D004058:Diffusion; D004195:Disease Models, Animal; D004791:Enzyme Inhibitors / Q000032:analysis* / Q000097:blood; D005122:Exudates and Transudates / Q000737:chemistry; D005260:Female; D006333:Heart Failure / Q000378:metabolism; D006801:Humans; D008168:Lung / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D010537:Peritoneum / Q000378:metabolism; D010741:Phospholipases A / Q000037:antagonists & inhibitors*; D010994:Pleura / Q000187:drug effects / Q000378:metabolism*; D010996:Pleural Effusion / Q000737:chemistry*; D011506:Proteins / Q000032:analysis*; D051381:Rats; D017207:Rats, Sprague-Dawley; D012907:Smoking / Q000097:blood / Q000378:metabolism; D013890:Thiourea / Q000009:adverse effects / Q000031:analogs & derivatives; D014598:Uteroglobin
D015415:Biomarkers; D001798:Blood Proteins; D004791:Enzyme Inhibitors; D011506:Proteins; C556389:SCGB1A1 protein, human; D014598:Uteroglobin; D003404:Creatinine; D010741:Phospholipases A; D013890:Thiourea; C005277:alpha-naphthyl thiourea